Showing 1801-1810 of 2123 results for "".
- Intrathecal Gene Therapy Approved for Adults, Older Children with Spinal Muscular Atrophyhttps://practicalneurology.com/news/intrathecal-gene-therapy-approved-for-adults-older-children-with-spinal-muscular-atrophy/2484610/The Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve; Novartis, Basel, Switzerland) for the treatment of people aged 2 years and older with spinal muscular atrophy (SMA) and a confirmed survival motor neuron 1 (SMN1) gene mutation. The adeno-associated vir
- First Thymidine Kinase 2 Deficiency Treatment Receives FDA Nodhttps://practicalneurology.com/news/first-thymidine-kinase-2-deficiency-treatment-receives-fda-nod/2484324/The Food and Drug Administration (FDA) has approved Kygevvi (doxecitine and doxribtimine; UCB, Brussels, Belgium) for the treatment of adult and pediatric patients with thymidine kinase 2 deficiency (TK2d) with an age of symptom onset at or before 12 years. Kygevvi is the first and only therapy a
- Blood-Based P-Tau181 Testing for Alzheimer’s Pathology Now Cleared by the FDA for the Primary Care Settinghttps://practicalneurology.com/news/blood-based-p-tau181-testing-for-alzheimers-pathology-now-cleared-by-the-fda-for-the-primary-care-setting/2484309/The Food and Drug Administration (FDA) has granted 510(k) clearance to Elecsys pTau181 (Roche, Basel, Switzerland), the first blood-based biomarker assay authorized to aid in the initial assessment of Alzheimer disease (AD) and other causes of cognitive decline for people aged ≥55 years in the pr
- Artificial Sweeteners Linked to Faster Cognitive Decline in Midlife Adultshttps://practicalneurology.com/news/artificial-sweeteners-linked-to-faster-cognitive-decline-in-midlife-adults/2484026/Higher consumption of low- and no-calorie sweeteners (LNCSs) was associated with accelerated cognitive decline, particularly in verbal fluency and global cognition, among adults aged <60 years. This finding from a longitudinal study published in Neurology contributes to a growing body
- 2024 McDonald Criteria Revisions Published in The Lancet Neurologyhttps://practicalneurology.com/news/2024-mcdonald-criteria-revisions-published-in-the-lancet-neurology/2483516/The 2024 revisions to the McDonald criteria for the diagnosis of multiple sclerosis (MS) have been published in The Lancet Neurology in September 2025, marking the first major update since 2017. The criteria were updated to reflect significant changes in the field, including an evolving
- FDA Greenlights Phase 2a Trial of Intranasal Foralumab in Multiple System Atrophyhttps://practicalneurology.com/news/fda-greenlights-phase-2a-trial-of-intranasal-foralumab-in-multiple-system-atrophy/2476103/The Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application, permitting the evaluation of treatment with intranasal foralumab (Tiziana Life Sciences, New York, NY) for people with multiple system atrophy (MSA) in a phase 2a clinical trial (NCT06868628). MSA i
- Accelerated FDA Approval Granted to First Treatment Targeting H3 K27M-Mutant Diffuse Midline Gliomahttps://practicalneurology.com/news/fda-grants-accelerated-approval-to-first-treatment-targeting-h3-k27m-mutant-diffuse-midline-glioma/2476100/The Food and Drug Administration (FDA) granted accelerated approval to Modeyso (dordaviprone; Jazz Pharmaceuticals, Dublin, Ireland) for the treatment of adults and children aged ≥1 year with diffuse midline glioma harboring the H3 K27M mutation with disease progression following prior therapy. M
- New Findings Related to Blarcamesine Treatment for People with Alzheimer Disease Presented at AAIC 2025https://practicalneurology.com/news/new-findings-related-to-blarcamesine-treatment-for-people-with-alzheimer-disease-presented-at-aaic-2025/2475931/According to an analysis of results from the phase 2b/3 ANAVEX2-73-AD-004 clinical trial (NCT04314934), treatment with Anavex2-73 (blarcamesine; Anavex Life Sciences, New York, NY) yielded greater clinical response for people with Alzheimer disease (AD) who carried the homozygous wild-type (WT) <
- Study Compares Nurtec ODT vs 14 Other Treatments for Acute Migrainehttps://practicalneurology.com/news/study-compares-nurtec-odt-vs-14-other-treatments-for-acute-migraine/2475275/Nurtec ODT (rimegepant; Pfizer, New York, NY) treatment for acute migraine was found to have superior or comparable efficacy and a more favorable safety profile compared with 14 other commonly used medications, which included triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), and compound a
- Sunosi Significantly Reduced Excessive Daytime Sleepiness and Obstructive Sleep Apnea Symptoms in Real-World Studyhttps://practicalneurology.com/news/sunosi-significantly-reduced-excessive-daytime-sleepiness-and-obstructive-sleep-apnea-symptoms-in-real-world-study/2475070/The results of a real-world analysis presented at the 2025 Annual Meeting of the Associated Professional Sleep Societies (APSS) show that Sunosi (solriamfetol; Axsome Therapeutics, New York, NY) significantly reduced symptoms of excessive daytime sleepiness (EDS) in individuals with obstructive s